Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ToleroMune HDM in House Dust Mite Allergy
NCT01447784Phase 2Completed
- Sponsor
- NIOX Group
- Start
- Sep 2011
- Primary completion
- May 2013
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HDM-SPIRE in house dust mite allergy (4 arms), sponsored by NIOX Group. Primary endpoint: Total Rhinoconjunctivitis Symptom Score at 47 weeks. Started Sep 2011; status: completed.
02
Drugs
HDM-SPIRE
03
Conditions
house dust mite allergy
Beyond the preview
Go deeper on NCT01447784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01447784.